The inner cell mass of the mammalian blastocyst contains individual cells capable of both proliferative "self-renewal" and differentiation into the various tissues of the adult body (4) . The "pluripotency" of these "embryonic stem cells" (ESC's) was first demonstrated in vitro, then later by their ability to participate in the production of all tissues in chimeric mice. ESC's have proven invaluable in the study of early development and tissue differentiation. But they gained their current celebrity with the discovery that homologous recombination could be used to alter their genomes, allowing the production of "designer mutations" in mice (1) .
Adult Stem Cells
A more specialized sort of stem cell apparently resides in adult tissues, particularly those that either continuously replenish the supply of mature cells (as in skin, bone marrow, and intestinal epithelium) or do so on demand following tissue damage (as in the liver) (5) . These "adult stem cells" (ASC's) were originally thought to be permanently committed to a single tissue lineage. But in recent years, some investigators have credited ASC's with the ability to shift lineages, to "transdifferentiate" under appropriate biological conditions (4, 5) . The claim remains controversial (5).
Regenerative Medicine
Great interest has arisen of late over the possibility that either ESC's or ASC's might be used to create a "regenerative medicine," in which damaged or defective tissues would be rejuvenated by the provision of stem cells as a source of tissue renewal (4) . Given their unquestioned pluripotency, ESC's are thought to offer the greater utility for regenerative medicine. It remains to be seen, however, whether means can be found to reliably direct differentiation of ESC's into desired, single lineages. Study of human ESC's has been severely constrained by federal policies designed to prevent the destruction of human blastocysts, which in turn deters the derivation of new lines of human ESC's.
Hematopoietic stem cells are the best characterized of ASC's (3). They can be purified and are now used in therapeutics. Other ASC's are in various stages of identification and characterization, but none appear close to clinical application. If ASC's were capable of transdifferentiation, they might also serve as acceptable surrogates for ESC's in regenerative medicine. But the "if" in this expectation is very large.
Cancer Stem Cells
Oncologists have long spoken of a "slow growth fraction" in tumors that resists eradication by therapies aimed at vigorously proliferating cells and can lead to tumor recurrence. Despite the apparently slow rate of proliferation, however, this subset of cells may be responsible for the continued expansion of a malignant tumor. Similarly, in efforts to transplant tumors from one animal to another, it is generally found that only a miniscule fraction of the tumor cells is capable of giving rise to a proliferating tumor in the recipient. The same small fraction of cells may be responsible for metastases, and for the emergence of drug resistance.
These observations have led to the suggestion that mutant versions of ASC's provide the reservoir from which the malignant cells of a full blown tumor emerge, and confer on their tumorigenic offspring some of the fundamental properties shared by stem cells and tumor cells (2, 3) . The evidence for such "cancer stem cells" (CSC's) is most persuasive for certain leukemias (3), but similar stem cells may also be responsible for solid tumors (2).
The capacity of ASC's for prolonged self-renewal renders them especially susceptible to the accumulation of multiple tumorigenic mutations, some of which might give rise to CSC's, and others of which might act downstream in the cellular lineage, in more restricted progenitor cells (2, 3) . It has been suggested that CSC's gain their capacity for continued propagation by retaining the molecular mechanisms responsible for self-renewal of ASC's. The further identification and characterization of CSC's may provide major advances in the management of malignant tumors. In particular, CSC's might well be the preferred cellular targets in the treatment of cancer (2) .
Genes which Alter Stem Cell Fate or Commitment to a Stratified Epithelial
Lineage 
Genes which Alter the Fate of Multipotent Stem Cells Influence Tumor Phenotype
Stem cells are the underlying cells which accumulate genetic alterations responsible for the development of nonmelenoma skin cancers. We recently demonstrated that constitutive expression of c-Myc in the basal layer of the epidermis and in hair follicles, the location of epidermal stem cells and multipotent stem cells, respectively, altered the fate of multipotent stem cells, diverting them to a sebaceous gland lineage (1) . To determine if alterations in the commitment of multipotent stem cells to different cell fates influenced tumor phenotype, we exposed this mouse model to a chemical carcinogenesis protocol and discovered that they were predisposed to develop sebaceous adenomas. Using an inducible c-Myc mouse model, we have been able to document that c-Myc directly regulates the expression of target genes involved in both Wnt and hedgehog signaling, which in turn influence the fate of multipotent stem cells, and thus tumor phenotype.
p63 is a Proto-Oncogene that Accelerates Skin Carcinogenesis
Genes that are active during normal development are frequently found to be dysregulated during neoplastic transformation. An example of a gene that is both required for normal development and involved in tumorigenesis is p63, a transcription factor that is transcribed into six different isoforms. Three of these isoforms contain a transactivation domain (TA) and are thought to be positive acting factors, while the other isoforms lack this domain ( N) and function in a dominant negative fashion. Although mutations in p63 are rare in human cancers, dysregulated expression of p63 is frequently observed in a subset of human epithelial cancers. To better understand the role of p63 during normal development and carcinogenesis, we used inducible mouse models to target TAp63α expression to single-layered lung epithelia or the epidermis. We found that ectopic expression of TAp63α in single-layered lung epithelia resulted in The epithelial components of the breast in both rodents and humans are thought to arise from a stem cell population that is capable of both self-renewal and lineage specific differentiation. During development and pregnancy, stem cells give rise to progenitors which in turn give rise to the three lineages found in the adult mammary gland: myoepithelial cells, ductal epithelial cells, and alveolar epithelial cells. We have developed in vitro culture system in which primary human mammary epithelial cells, isolated from reduction mammoplasties, are cultured as "mammospheres" on non-adherent surfaces. We have demonstrated that mammospheres are highly enriched in undifferentiated cells capable of differentiating into all lineages found in the mature mammary gland. Utilizing retroviral marking studies, we demonstrate that mammospheres are clonally derived and do not result from cellular aggregation.
We have utilized mammosphere cultures to elucidate pathways that regulate the self-renewal of normal mammary stem cells, as well as processes the regulate cell fate determination. We demonstrate that both leukemia inhibitory factor, and hedgehog signaling are involved in self-renewal of mammary stem cells. LIF, produced by mammary stromal cells, is able to activate stat-3, increasing mammosphere formation. The hedgehog receptor, Indian hedgehog, as well as its binding partner Smoothened, and the transcription factor GLI-1 are all expressed at higher levels in mammospheres than in cells induced to differentiate by plating on a collagen substratum. Exogenous sonic hedgehog promotes mammosphere formation, whereas inhibition of this pathway, utilizing Cyclopamine inhibits mammosphere formation. These studies suggest that both LIF and hedgehog signaling are involved in the self-renewal of mammary stem cells. We have also demonstrated that Notch pathway is involved in mammary stem cells self-renewal as well as lineage specific differentiation. Utilizing the mammosphere system, we demonstrate that Notch signaling acts on mammary stem cells to promote self-renewal as demonstrated by a 10-fold increase in secondary mammosphere formation upon addition of a Notch activating DSL peptide. In addition to acting on stem cells, Notch signaling is also able to act on multi-potent progenitor cells, facilitating myoepithelial lineage commitment and proliferation. Stimulation of this pathway also promotes branching morphogenesis in three dimensional Matrigel cultures. This effect is completely inhibited by a Notch-4 blocking antibody or a gamma secretase inhibitor that blocks Notch processing. In contrast to the effects of Notch signaling on mammary stem/progenitor cells, modulation of this pathway has no discernable effect on fully committed mammary cells. We have also demonstrated that human mammospheres are able to reconstitute the cleared fatpads of NOD/SCID mice. We have utilized mammosphere-derived cultures to examine the origin of estrogen receptor positive cells within the breast. We have demonstrated that mammospheres contain estrogen receptor positive cells which are proliferating. We propose that these cells may be precursors of the quiescent estrogen receptor expressing population found in fully differentiated glands.
We hypothesize that mammary stem cells or their immediate progeny are targets for transformation during carcinogenesis. One of the key events in carcinogenesis may involve disregulation of self-renewal pathways of normal mammary stem cells. Although there has been considerable research regarding the spectrum of mutations involved in mammary carcinogenesis, much less research has focused on the cell of origin of breast carcinoma and the relationship of this cell of origin to cellular phenotypes. The genetic defects that disregulate stem and progenitor cells, simultaneously may effect differentiation pathways, generating the phenotypic heterogeneity found in breast tumors. Consistent with this model, we have found that breast tumors isolated from different patients contain a small sub-population of tumorigenic cells with the cell-surface phenotype ESA+CD44+CD24 −/low Lineage − that have properties of "tumor stem cells." As few as 200 of these cells are able to consistently generate tumors in NOD/SCID mice, while the vast majority of cells in these tumors that lack this phenotype are incapable of tumor formation even when tens of thousands of cells are injected into mice. Consistent with a stem cell model, the ESA+CD44+CD24 −/low Lineage − cells generate tumors that recapitulate the entire phenotypic heterogeneity found in original tumors. The tumor stem cell model has important biological, as well as therapeutic implications. For example, molecular profiling studies identifying subsets of breast carcinoma with distinct molecular signatures and clinical outcomes may reflect the cell of origin as well as the mutation profile. Based on this concept, we have proposed a model in which the molecular profiles of breast carcinoma with distinct clinical outcomes arise from transformation of distinct stem and progenitor cells.
The identification of tumor stem cells in situ may have diagnostic and prognostic significance. Furthermore, if tumors arise through mutations in stem and progenitor cells, it will be most important to identify and develop strategies to eliminate this cell population. An alternative strategy involves the development of agents which induce irreversible differentiation of these populations. The existence of a subpopulation within tumors, which drive tumorigenesis, also has important implications for the therapy of breast cancer. Current therapies developed by virtue of their ability to induce tumor regression may selectively target more differentiated cells in tumors, while leaving the tumor stem cell population intact. Tumor stem cells may then regenerate the tumor, contributing to relapse. More effective therapies, therefore, will require the targeting and elimination of tumor stem cell populations in breast cancer patients.
